

Antimicrobial resistance of Enterococcus cecorum: ECOFF determination

Jeanne Laurentie, Gwenaelle Mourand, Pauline Grippon, Sylviane Furlan, Claire Chauvin, Eric Jouy, Pascale Serror, Isabelle Kempf

▶ To cite this version:

Jeanne Laurentie, Gwenaelle Mourand, Pauline Grippon, Sylviane Furlan, Claire Chauvin, et al.. Antimicrobial resistance of Enterococcus cecorum: ECOFF determination. 2023. anses-04188278

HAL Id: anses-04188278 https://anses.hal.science/anses-04188278v1

Preprint submitted on 25 Aug 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

bioRxiv preprint doi: https://doi.org/10.1101/2022.10.19.512977; this version posted October 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

1	Antimicrobial resistance of Enterococcus cecorum: ECOFF determination							
2	Jeanne Laurentie ^{ab} , Gwenaelle Mourand ^a , Pauline Grippon ^a , Sylviane Furlan ^b , Claire							
3	Chauvin ^a , Eric Jouy ^a , Pascale Serror ^b and Isabelle Kempf ^a *							
4								
5	^a ANSES, Laboratoire de Ploufragan-Plouzané-Niort, Ploufragan, France							
6	^b Université Paris-Saclay, INRAE, AgroParisTech, Micalis Institute, 78350 Jouy en Josas,							
7	France							
8								
9	*Corresponding Author: Isabelle Kempf, French Agency for Food, Environmental and							
10	Occupational Health & Safety (ANSES), Ploufragan-Plouzané-Niort Laboratory, Zoopole les							
11	croix, 22440 Ploufragan, France							
12	Phone: 33 2 96 01 62 81							
13	Fax: 33 2 96 01 62 73							
14	Email: <u>isabelle.kempf@anses.fr</u>							
15								
16								
17	& Co-corresponding author: Pascale Serror, Université Paris-Saclay, INRAE, AgroParisTech,							
18	Micalis Institute, 78350 Jouy en Josas, France							
19	Phone: 33 1 34 65 21 66							
20	Fax: 33 1 34 65 20 65							
21	Email: <u>pascale.serror@inrae.fr</u>							
22								
23								
24 25	Key-words: <i>Enterococcus cecorum</i> , epidemiological cut-offs, disc diffusion, broth microdilution, resistance genes, MICs							
26	Running title: antimicrobial resistance of Enterococcus cecorum							

27

28 ABSTRACT

29 Enterococcus cecorum, a commensal Gram-positive bacterium of the chicken gut, has 30 emerged as a worldwide cause of lameness in poultry, particularly in fast-growing broilers. It is responsible for osteomyelitis, spondylitis and femoral head necrosis, causing animal 31 32 suffering, mortality and antimicrobial use. Research on the antimicrobial resistance of E. cecorum clinical isolates in France is scarce, and epidemiological cut-off (ECOFF) values 33 34 unknown. To determine tentative ECOFF (CO_{WT}) values for *E. cecorum* and to investigate the 35 antimicrobial resistance patterns of isolates from mainly French broilers, we tested the 36 susceptibility of a collection of commensal and clinical isolates (n=208) to 29 antimicrobials 37 by the disc diffusion (DD) method. We also determined the minimum inhibitory 38 concentrations (MICs) of 23 antimicrobials by the broth micro-dilution method. To detect 39 chromosomal mutations conferring antimicrobial resistance, we investigated the genomes of 118 E. cecorum isolates mainly obtained from infectious sites and previously described in the 40 41 literature. We determined the CO_{WT} values for more than 20 antimicrobials and identified two chromosomal mutations explaining fluoroquinolone resistance. The DD method appears 42 43 better suited for detecting E. cecorum antimicrobial resistance. Although tetracycline and erythromycin resistances were persistent in clinical and non-clinical isolates, we found little 44 45 or no resistance to medically important antimicrobials.

46

47 **INTRODUCTION**

48 Enterococcus cecorum, first described as Streptococcus cecorum in 1983 (1), is a dominant 49 commensal Gram-positive bacterium found in the intestinal microbiota of healthy adult chickens (1). Since 2002, it has been emerging in poultry production as a pathogen 50 51 responsible for lameness, osteomyelitis and spondylitis with increased mortality rates in 52 broiler productions and to a lesser extent in ducks and other avian species (2). The development of E. cecorum infections is multifactorial, and depends on predisposing factors 53 54 related to host genetics, rapid growth, feed composition, husbandry procedures and animal 55 density, all in combination with the bacterium's pathogenic potential (3-5).

56 There are no vaccines against E. cecorum, and protective measures can only include biosecurity and good poultry management. If an E. cecorum infection is diagnosed, 57 antimicrobials may be used as soon as possible to prevent further progression (4). Indeed, 58 59 antimicrobial therapy is ineffective for paralysed birds. The choice of the antimicrobial compound to be used should be based on the susceptibility of the isolated strain. As defined 60 61 by EUCAST (https://mic.eucast.org/), epidemiological cut-off (ECOFF) values distinguish microorganisms without (wild type) and with phenotypically detectable acquired resistance 62 63 mechanisms (non-wild type) to the agent in question, and a micro-organism is defined as wild type (WT) for a species by the absence of acquired and mutational resistance mechanisms to 64 the drug in question. On the other hand, clinical breakpoints are determined on the basis of 65 dosages, pharmacokinetics, resistance mechanisms, MIC distributions, inhibition zone 66 67 diameters and more recently, pharmacodynamics and ECOFFs. A micro-organism is thus 68 defined as clinically susceptible by a level of antimicrobial activity associated with a high 69 likelihood of therapeutic success. Despite the few MIC criteria for E. cecorum proposed by 70 Borst et al. (6) for several antimicrobials, there are no ECOFFs nor clinical breakpoints

71 specifically for *E. cecorum*. Few studies on the antimicrobial resistance of *E. cecorum* are

available and interpretation is usually based on enterococci ECOFFs or breakpoints (6-9).

Resistance to tetracycline and erythromycin is the most commonly reported, but resistance to aminoglycosides and β -lactams is sometimes detected (4, 9). To date, few acquired antimicrobial resistance genes (9) and no resistance-conferring mutations have been associated with antimicrobial resistance phenotypes in *E. cecorum*.

The aims of this study were to analyse by disc diffusion (DD) and broth micro-dilution 77 78 (BMD) methods a large collection of commensal and clinical *E. cecorum* isolates to: (i) 79 establish provisional ECOFF (COWT) values for E. cecorum inhibition zone diameters and 80 minimum inhibitory concentrations (MICs); (ii) to evaluate the correlation between inhibition 81 zone diameters and MIC values; and (iii) to analyse the relationship between observed 82 phenotypes and the genotypes of previously studied *E. cecorum* clinical isolates (J. Laurentie, 83 V. Loux, C. Hennequet-Antier, E. Chambellon, J. Deschamps, A. Trotereau, S. Furlan, C. Darrigo, F. Kempf, J. Lao, M. Milhes, C. Roques, B. Quinquis, C. Vandecasteele, R. Boyer, 84 85 O. Bouchez, F. Repoila, J. Le Guennec, H. Chiapello, R. Briandet, E. Helloin, C. Schouler, I. Kempf, and P. Serror, submitted for publication). 86

87

88 MATERIAL AND METHODS

89 **Bacterial Isolates.**

The present study investigated 208 isolates of *E. cecorum*. Of these, 118 were previously
described in the literature isolates (J. Laurentie, V. Loux, C. Hennequet-Antier, E.
Chambellon, J. Deschamps, A. Trotereau, S. Furlan, C. Darrigo, F. Kempf, J. Lao, M. Milhes,
C. Roques, B. Quinquis, C. Vandecasteele, R. Boyer, O. Bouchez, F. Repoila, J. Le Guennec,
H. Chiapello, R. Briandet, E. Helloin, C. Schouler, I. Kempf, and P. Serror, submitted for
publication), five were co-isolated with *E. coli* from an infected bird, and 85 were isolated

between 2019 and 2021 in France from the caecal contents or pooled faecal samples of
healthy birds collected from hatcheries, farms and slaughterhouses (Table S1). A selective
medium specific to *E. cecorum* was used to isolate commensal strains (S. Furlan & P. Serror,
personal communication).

100 Disc diffusion method. The DD method was applied to 29 antimicrobials or 101 associations of antimicrobials of importance in either veterinary or human medicine (amoxicillin 25 μ g, ampicillin 2 μ g, cefotaxime 5 μ g, ceftaroline 5 μ g, imipenem 10 μ g, 102 103 norfloxacin 10 μ g, ciprofloxacin 5 μ g, levofloxacin 5 μ g, vancomycin 5 μ g, teicoplanin 30 μ g, 104 gentamicin 500 µg, streptomycin 300 µg, spectinomycin 100 µg, lincomycin-spectinomycin 2 105 $\mu g/100 \mu g$, lincomycin 15 μg , erythromycin 15 μg , spiramycin 100 μg , tylosin 30 μg , quinupristin-dalfopristin 15 µg, tetracycline 30 µg, doxycycline 30 µg, tigecycline 15 µg, 106 tiamulin 30 µg, fosfomycin 200 µg, nitrofurantoin 100 µg, linezolid 10 µg, chloramphenicol 107 30 µg, bacitracin 130 µg and rifampicin 5 µg) on Mueller-Hinton agar plates supplemented 108 with 5% mechanically defibrinated horse blood and 20 mg/L β -NAD (MH-F agar). All the 109 procedures were in keeping with the EUCAST DD method (10). Plates were inoculated by 110 swabbing in three directions with a 0.5 McFarland bacterial suspension (5 x 10^7 colonv 111 112 forming units (CFU)/mL), prepared in saline solution (0.85% NaCl). Inhibition zone diameters were measured after 18 h \pm 2 h of incubation (and 24 h more for glycopeptides) at 113 114 $35^{\circ}C \pm 2^{\circ}C$ in 5% CO₂, as recommended for Streptococcus pneumoniae. As there is no 115 recommended reference strain for E. cecorum, S. pneumoniae (CIP 104340) was used as a 116 proxy.

Broth micro-dilution method. The BMD method (11) was used to determine the MICs of 23 antimicrobial agents for *E. cecorum* isolates placed in 96-well microtitre plates. Firstly, 50 μ L of sterile water was placed in each well, then 50 μ L of the antimicrobial solution was added to each well in the first column of the microtitre plate. Serial two-fold dilutions of the antimicrobial solutions were performed by transferring 50 μ L from the first

122 column to the second one, and subsequently up to the lowest tested dilution as described in

Figure 1. The microtitre plates were stored at -70°C before use.

The day before the MIC determination assay, E. cecorum isolates were inoculated onto 124 Columbia agar supplemented with 5% of sheep blood from Bio-Rad and incubated at 35°C 125 126 for 24 hours in 5% CO₂. Next, 0.5 McFarland bacterial suspensions prepared in saline solution were diluted 1:100 in cation-adjusted Mueller-Hinton fastidious (MH-F) broth 127 (Thermo ScientificTM) in order to reach the final concentration of 5×10^5 CFU/mL. Finally, 128 50 µL of the suspension was added to each well. One well per plate was used as a positive 129 130 control (wells with only the bacterial suspension) and one as a negative control (wells with only sterile cation-adjusted MH-F broth used to prepare the inoculum). The MICs were read 131 after 18 ± 2 h of incubation at 35 ± 2 °C and 24 h more for streptomycin, as recommended for 132 enterococci. As there is no reference for E. cecorum, S. pneumoniae (CIP 104340) was used 133 134 as a proxy.

Cut-off value determination and statistical tests. For the DD method, the 135 normalised resistance interpretation (NRI) method was used with permission from the patent 136 137 holder, Bioscand AB, Täby, Sweden (European patent no. 1383913, US patent no. 7,465,559) to determine the tentative cut-off value for each of the molecules tested. In the event of outlier 138 values, a maximum of 1% (n=2 isolates) of extremely high diameter values were removed for 139 140 For MICs, ECOFFFinder analysis. the tool 141 (https://www.eucast.org/mic distributions and ecoffs/, v2.1) was used to determine the 142 tentative cut-off value for each molecule tested without removing any outliers. The temporary cut-off considered was the ECOFF set at 99% of the estimated wild-type population. Isolates 143 resistant to at least three different antimicrobial families were considered multi-drug resistant 144 145 (MDR).

Scattergrams were plotted to compare the concordance between the DD and MIC categorisation of isolates. The percentage of discrepancy (Pd) was calculated for each antimicrobial agent tested by both methods. For a value less than 5%, the classifications obtained with the two methods were considered as equivalent (**Table S2**).

Statistically significant differences in the distribution of wild-type (WT) and non-wild-type (NWT) isolates of different origins (clinical poultry (CP) versus non-clinical poultry (NCP) isolates) according to DD results were confirmed by the Chi² test or Fisher exact test for five or fewer isolates, for a p-value less than 0.05

Identification of gene mutations. Mutations in genes that may be involved in antimicrobial resistance were identified by multi-alignment of the corresponding proteins using MultAlin (12). Only mutations specific to NWT isolates were selected.

157

158 **RESULTS**

Determination of inhibition zone diameters. The inhibition zone diameters were determined for the 208 *E. cecorum* isolates using the DD method. For each DD assay, the results obtained for the reference strain and the inoculation density complied with EUCAST recommendations (data not shown).

163 The temporary cut-Off (CO_{WT}) value was determined for 25 molecules (**Figure 2, Table S3**). 164 The distribution of the diameters of four antimicrobials is shown in **Figure S1**, while WT and 165 NWT isolates are presented in **Figure 2**. The heterogeneity of diameters for four β -lactams 166 (ampicillin, amoxicillin, cefotaxime and ceftaroline) prevented the determination of CO_{WT} 167 values.

We tested several molecules for a few antimicrobial families: there was almost total agreement between DD results obtained for ciprofloxacin and levofloxacin, with respectively 97.6% and 97.1% of WT isolates, whereas 74.5% were categorised as WT for norfloxacin. The concordance between spiramycin and tylosin was 98.6% and yielded similar rates of NWT isolates (48.1% to 47.6%). The classification according to DD for spiramycin and tylosin was similar to that obtained for erythromycin for respectively 93.3% and 92.8% of isolates. Most of the isolates tested using DD were resistant to tetracycline and doxycycline (respectively 95.7% and 93.8%, with an agreement of 98%) while none showed resistance to tigecycline.

Globally, there were no NWT isolates for imipenem and fewer than ten for ciprofloxacin (n=5) and levofloxacin (n=6), teicoplanin (n=1), vancomycin (n=8), gentamicin (n=1), streptomycin (n=5), fosfomycin (n=2), nitrofurantoin (n=2), linezolid (n=2), chloramphenicol (n=1) and rifampicin (n=7). Thirteen percent of the isolates were NWT for tiamulin. Of all the isolates, 43.3% were found to be MDR to up to eight different antimicrobial families, including glycopeptides. Only three isolates (1.4%) were susceptible to all the molecules tested.

184 Distributions of WT and NWT isolates according to their origin (Table 1) showed that 185 identical rates of CP and NCP isolates were NWT for tetracycline and doxycycline, as were 186 for bacitracin. There were significant differences in the ratios of WT and NWT isolates for 187 erythromycin, as there were respectively 65% and 40% of NWT for CP and NCP (p= 0.00038); likewise for norfloxacin, where the corresponding figures for NWT were 32% and 188 18% (p=0.025). On the other hand, for spectinomycin and lincomycin-spectinomycin, 21% of 189 190 NCP isolates were NWT for both compared with 4% of CP isolates for spectinomycin $(p=8.7 \times 10^{-5})$ and 8% for lincomycin-spectinomycin $(p=6 \times 10^{-3})$. 191

192 Determination of minimal inhibitory concentrations (MICs).

For each MIC determination assay, the results obtained for the reference strain complied with EUCAST recommendations (data not shown) (EUCAST, 2019). The distributions of the MICs of 23 antimicrobials and their corresponding MIC₅₀ and MIC₉₀ values are displayed in

Figure 1. MIC values above the tested range were observed for seven antimicrobials 196 197 (vancomycin, teicoplanin, tylosin, tetracycline, doxycycline, bacitracin and avilamycin). For 198 glycopeptides, doxycycline and bacitracin, only one, two or three strains were concerned. The 199 greatest proportion of isolates with MIC values above the tested range were found for 200 tetracycline (n=128, 61.5%), tylosin (n=54, 26%) and avilamycin (n=41, 19.7%). For 201 teicoplanin, tetracycline and rifampicin, the MIC₅₀ and MIC₉₀ values were equal (respectively 202 0.125 mg/L, 256 mg/L and 0.125 mg/L). For ten (ampicillin, amoxicillin, vancomycin, 203 gentamicin, doxycycline, tigecycline, chloramphenicol, linezolid, avilamycin and 204 daptomycin) of the tested antimicrobials, the values between MIC_{90} and MIC_{50} differed by 205 only one dilution step.

CO_{WT} values were calculated for 17 antimicrobial agents for the complete *E. cecorum* dataset 206 207 (Figure 2). No value could be computed for beta-lactams nor for spectinomycin due to the 208 heterogeneity of the population distribution. For tetracycline, doxycycline and avilamycin, CO_{WT} values were determined through a graphical representation due to the number of NWT 209 strains. For seven antimicrobial agents, the percentages of NWT isolates were high to 210 211 extremely high (tylosin (38%), spiramycin (38.5%), lincomycin (42.8%), erythromycin 212 (44.2%), tetracycline (77.9%), doxycycline (81.7%) and avilamycin (90.9), whatever their origin. 213

Comparison between MICs and inhibition zone diameters for *E. cecorum*. Table S2 highlights the difference in interpretation between DD and BMD methods. For nine antimicrobial agents, the Pd values were lower than 5% (levofloxacin 4.8%, vancomycin 3.85%, teicoplanin 0.5%, gentamicin 1%, quinupristin-dalfopristin (QDF) 2.9%, tigecycline 0.0%, chloramphenicol 0.5%, linezolid 1% and rifampicin 2.4%), meaning that there were very few differences in WT/NWT categorisation between the methods. In contrast, nine antimicrobial agents yielded Pd values higher than 5% (ciprofloxacin 7.7%, streptomycin 221 9.6%, lincomycin 24.5%, erythromycin 16.4%, spiramycin 14.4%, tylosin 15.4%, 222 doxycycline 14.9%, tetracycline 17.8%, and bacitracin 17.8%). For macrolides, lincosamides 223 and streptogramins (MLS), tetracyclines and bacitracin, CO_{WT} values determined by the DD 224 method gave more NWT strains than BMD did. Conversely, for ciprofloxacin and 225 streptomycin, CO_{WT} values determined by the BMD method gave more NWT strains than 226 DD.

227 Consistent gene content and expression of resistance phenotypes. In our previous genomic

study isolates (J. Laurentie, V. Loux, C. Hennequet-Antier, E. Chambellon, J. Deschamps, A.

229 Trotereau, S. Furlan, C. Darrigo, F. Kempf, J. Lao, M. Milhes, C. Roques, B. Quinquis, C.

Vandecasteele, R. Boyer, O. Bouchez, F. Repoila, J. Le Guennec, H. Chiapello, R. Briandet,
E. Helloin, C. Schouler, I. Kempf, and P. Serror, submitted for publication), antimicrobial
resistance genes were identified on the genomes of 118 isolates and correspondences between
their genomic content and their resistance phenotype are presented below (Table S4).

234 The 114 tetracycline-NWT isolates with sequenced genomes carried at least one tetracycline 235 resistance gene. The tet(M) tet(L) association was the most frequent (n=61), followed by 236 tet(M) gene only (n=47), the associated tet(M) tet(O) genes (n=2), tet(M), tet(L) and tet(O)237 (n=1), tet(M) and tet(44) (n=1), the tet(O) gene (n=1) and the tet(L) gene (n=1). Thus, the ribosomal protection gene tet(M) is the most frequent tetracycline resistance gene (n=112) in 238 239 our E. cecorum isolates, as reported for E. cecorum (9) and other enterococci [16]. No 240 tetracycline-resistance gene was detected in the genomes available for the four tetracycline-241 WT isolates. As expected, most of our erm-positive isolates were NWT for erythromycin (78/80, 97.5%) and lincomycin (77/80, 96.3%). Four isolates bearing mefA and lnuC were 242 243 NWT for lincomycin but not the other tested MLSs. The four isolates possessing the *ermG*, 244 mefA, msrD and lnuC genes were NWT for erythromycin, but only one was also NWT for 245 lincomycin, spiramycin and tylosin. Six of the eight QDF-resistant isolates for which genomic 246 sequences were available carried the *ermB* or *ermG* gene, but no other acquired resistance 247 mechanisms could be detected in the remaining two. Two isolates with an ermB gene were 248 found WT for macrolides. These diverse discrepancies between MLS phenotypes and genotypes were not investigated further, but could result from the poor or lack of expression 249 250 of the encoded proteins, and/or the presence of unknown resistance genes or mutations. 251 Acquired resistance genes were identified to explain resistance to gentamicin, streptomycin or 252 spectinomycin in six aminoglycoside-resistant isolates. The spc (or ant(9)-Ia) gene was 253 detected in two spectromycin-resistant isolates. Four isolates contained aadE (ant(6)-Ia), an 254 aminoglycoside-nucleotidytransferase conferring resistance to streptomycin, and were found 255 resistant to this antimicrobial according to both BMD and DD methods. Two isolates from the 256 United States have been reported to carry the aph(3')-III gene conferring resistance to 257 kanamycin (9), but this aminoglycoside was not tested. According to the DD or BMD method, 258 26.4% or 16.3% of isolates were NWT for bacitracin. Among the sequenced isolates, 27 were 259 found to be NWT using DD and 24 of these NWTs had a bacitracin resistance operon, with 260 uppP2, bcrB, bcrA and bcrR genes. This operon was also detected in only four of the 91 261 bacitracin-WT sequenced isolates. With regard to glycopeptides, seven isolates were 262 classified as NWT for vancomycin according to DD. One of them was also NWT for teicoplanin and a vanA operon was detected in its genome. No other glycopeptide resistance 263 264 genes were detected.

For fluoroquinolones, we looked in the 118 available genome sequences for chromosomal mutations that could explain resistance as they may target DNA gyrase and topoisomerase IV. The three ciprofloxacin- and levofloxacin-NWT sequenced isolates harboured a mutation in the GyrA quinolone resistance-determining region (either S83Y or S83V), only detected in these genomes. Moreover, a mutation in ParC (S82I) was also highlighted in 24/35 of norfloxacin-NWT isolates. 271

272 DISCUSSION

273 For the first time, the CO_{WT} values for 25 out of 29 and 20 out of 23 molecules tested using 274 the DD or BMD methods respectively were calculated with the EUCAST method adapted to 275 *E. cecorum*, (or in three cases by visual inspection for BMD) the main exception being for β -276 lactams, which have a heterogeneous distribution. The availability of tentative ECOFF values is the first step in monitoring the AMR of a bacterial species. Our data are based on results 277 278 from one laboratory only; however, they concern a variety of commensal and clinical isolates 279 collected over more than 37 years. They will no doubt contribute to the definition of official 280 interpretative criteria for E. cecorum, a major poultry pathogen. Data from other countries 281 relative to multiple and diverse sources and a large number of isolates are now needed to set 282 recognised ECOFFs with the expected precise estimates (13).

283 This work reveals that the concentration criteria currently used to classify E. cecorum isolates, 284 based on the breakpoints recommended for enterococci or ECOFF values for E. faecalis and 285 E. faecium, do not always properly distinguish WT from non-WT, while the ECOFF values for S. pneumoniae coincide more frequently (Table 2). Part of this difference is probably 286 287 related to the similar growth conditions under CO₂ 5% for *E. cecorum* and *S. pneumoniae*. Overall, discrepancies between the distribution of MICs and CO_{WT} or ECOFF values for E. 288 289 cecorum and S. pneumoniae, E. faecium or E. faecalis were observed for aminoglycosides, 290 tigecycline, avilamycin and bacitracin. Indeed, E. cecorum seems susceptible to moderate 291 concentrations of aminoglycosides, and the CO_{WT} determined for streptomycin (32 mg/L) and 292 gentamicin (4 mg/L) are lower than the ECOFF for E. faecium (respectively 128 mg/L and 32 293 mg/L) or *E. faecalis* (512 and 64 mg/L). Currently there are no ECOFF values for these 294 antimicrobials for S. pneumoniae. The calculated CO_{WT} for tigecycline is 4 mg/L, which is much higher than the ECOFF for S. pneumoniae (0.125 mg/L) or E. faecium (0.25 mg/L). 295

296 Both the MIC₅₀ and MIC₉₀ for tigecycline are low (respectively 0.5 and 1 mg/L) and all 208 297 isolates were classified as WT according to both DD and BMD methods. Our MIC results for avilamycin yielded a MIC₅₀ of 64 mg/L and a CO_{WT} value of 1 mg/mL compared to ECOFF 298 299 values of 8 mg/L or 16 mg/L respectively for E. faecalis or E. faecium, resulting in a 300 percentage of avilamycin-NWT E. cecorum of 91.0%. The calculated CO_{WT} for bacitracin was 301 also three double dilutions lower than the ECOFF value for E. faecium. The size of the NWT 302 population may also bias the determination of the CO_{WT}. We could not calculate the CO_{WT} of 303 beta-lactams for E. cecorum. The MIC₉₀ values for ampicillin and amoxicillin were lower 304 (0.25 mg/L and 0.125 mg/L respectively) than the MICs reported for E. faecalis or E. faecium 305 (https://mic.eucast.org/), a feature of *E. cecorum* already reported for penicillin by Jung et al. 306 (4). Using an amoxicillin breakpoint of 0.25 mg/L like Borst et al. (6) we managed to classify 307 nine out of 208 isolates as amoxicillin-resistant (4.0%) in contrast to the 26.3% NWT rate 308 reported by the authors. This observation suggests a low rate of amoxicillin resistance in our collection. 309

310 A comparison of the interpretations between the DD and BMD methods used and the gene 311 content of the sequenced isolates shows that the DD method is more consistent with the gene 312 content. For erythromycin, for example, using the DD method, 82/84 NWTs have an ermgene and only two WT isolates carry one. Conversely, according to the BMD method, 13 313 314 isolates of the 47 considered as WT carry an *erm* gene and 66/71 of the NWTs carry one. The 315 same is true, to a lesser extent, for tetracycline: 114/114 NWTs classified by the DD method 316 carried tetracycline resistance genes while 110/114 are considered NWTs by the BMD 317 method and carry at least one tet gene. These different observations suggest that under the 318 conditions tested, the DD method and the corresponding calculated CO_{WT} value are more 319 accurate in determining the resistance of *E. cecorum*.

Despite a significant decrease in the use of antimicrobials in animals during the last ten years 320 321 in France, Europe and the USA, tetracyclines and penicillins are still used extensively (14). 322 The prevalence of NWT isolates for tetracycline was extremely high, as previously observed 323 for enterococci from French broilers (15). High rates have also been reported for E. cecorum in other countries (70%) (4), as well as for E. faecium (80.3%) and E. faecalis (78.5%) (16). 324 325 The prevalence of NWT isolates for erythromycin, a 14-membered macrolide, was quite high (44.7% for BMD and 54.8% for DD), although lower than in data previously reported for E. 326 327 cecorum (70% (4)), and similar to those reported for European broiler isolates of E. faecium 328 (57.0% %) and E. faecalis (56.6%) (16). CP isolates were more frequently resistant to MLSs 329 (erythromycin, spiramycin and tylosin) than NCP ones. This difference has already been observed in other studies (6, 7, 9, 17). Indeed, macrolides are used for therapy for poultry, 330 331 which may explain the prevalence of resistance in clinical isolates. A slightly higher number 332 of E. cecorum strains were found to be NWT for lincomycin (60.6% according to DD), but with a MIC₅₀ of 1 mg/L, this species does not seem naturally resistant to lincosamides, unlike 333 several other Enterococcus species (e.g. E. faecalis, E. avium, E. gallinarum, E. 334 335 casseliflavus). The association of lincomycin (66% of NWTs in CP isolates) and 336 spectinomycin (4% of NWTs in CP isolates) highlights the benefits of lincomycin, as only 8% of CP isolates are NWT for lincomycin-spectinomycin. This susceptibility may explain the 337 reported use in Germany of the antimicrobial association during the first week of life to 338 339 control E. cecorum isolates (18). Similarly, the MIC₉₀ of quinopristin-dalfopristin was low (2 340 mg/L) for our *E. cecorum* isolates, and precludes an intrinsic resistance to these compounds, 341 unlike E. faecalis. Indeed, only 6.2% of isolates were classified as NWT for quinopristin-342 dalfopristin. It should be remembered that high occurrences of quinopristin-dalfopristin-NWT E. faecium were observed in poultry in France and other European countries several years 343 ago, probably due to the use of virginiamycin as a growth promoter in Europe up to 1999 (15, 344

19). Unfortunately, this quinopristin-dalfopristin resistance apparently persisted in *E. faecium*up to recent observations, maybe as a result of co-selection by other antimicrobials used for
therapy (19). Different resistance genes to MLS (*ermB, ermG, lnuB, merfA, msrD, linB, lnuB, lnuC* and *lnuD* have already been identified by Sharma et al. in *E. cecorum* genomes and
associated with resistance phenotypes (9).

350 Avilamycin is an oligosaccharide antimicrobial used as a growth promoter among poultry in 351 the European Union up to 2006. A link between the consumption of avilamycin and resistance 352 of E. faecium to this antimicrobial has been demonstrated in the literature (20, 21). In France, 353 the percentages of broilers or turkeys with avilamycin-resistant E. faecium were respectively 354 8.3% and 21.8% in 2007 (22). Thus the high level of resistance of E. cecorum (90.8% of 355 NWT, and a MIC₅₀ of 64 mg/L) to an antimicrobial that is no longer used is rather 356 unexpected, but we could not detect the previously described avilamycin resistance 357 mechanisms, i.e. the *emtA* gene or mutations in L16 (20).

358 Very few isolates were classified as NWT for chloramphenicol, fosfomycin and 359 nitrofurantoin. A low prevalence of chloramphenicol resistance has also been reported in 360 other studies for *E. cecorum* or *E. faecium* (4, 23). Since 1994, chloramphenicol is forbidden 361 in Europe for food-producing animals, but other phenicols (e.g. florfenicol) are authorised, mainly for pigs and cattle, explaining more frequent chloramphenicol-NWT E. faecalis in 362 363 these productions (23). Fosfomycin has rarely been tested against poultry enterococci. 364 According to Schwaiger et al. (24) about 5% of E. faecalis from cloacal swabs of organically 365 and conventionally kept laying hens were resistant to fosfomycin. In enterococci, fosfomycin 366 can be related to mutations in the target enzyme MurA, or enzymatic modification of 367 fosfomycin, linked to the acquisition of transferable fosB genes or the high expression of the 368 fosX gene (25, 26). Consistently with Suyemoto et al. (27) who detected no nitrofurantoin resistance among 32 *E. cecorum* strains, the prevalence of this resistance in our collection is
below 1%.

371 Prevalence of E. cecorum resistance to critically important antimicrobials in human medicine is quite low, confirming our prediction from genome analysis isolates (J. Laurentie, V. Loux, 372 373 C. Hennequet-Antier, E. Chambellon, J. Deschamps, A. Trotereau, S. Furlan, C. Darrigo, F. 374 Kempf, J. Lao, M. Milhes, C. Roques, B. Quinquis, C. Vandecasteele, R. Boyer, O. Bouchez, F. Repoila, J. Le Guennec, H. Chiapello, R. Briandet, E. Helloin, C. Schouler, I. Kempf, and 375 376 P. Serror, submitted for publication). Low rates of linezolid NWT isolates agree with the low 377 detection levels among broilers in E. faecium and E. faecalis in 2012-2013 (15, 23). However, 378 recent studies on animal samples inoculated onto linezolid-supplemented media revealed that linezolid-resistant enterococci (or staphylococci) may be frequently present although not 379 380 detected when analysing only strains from the dominant enterococci population isolated on 381 non-supplemented media (28). Linezolid has never been used in animal production, but 382 antimicrobial resistance mechanisms evidenced in animal isolates (e.g. cfr, optrA and poxtA 383 genes) could explain the co-selection of the described linezolid-resistant strains by the use of 384 other commonly used antimicrobials (e.g. tetracyclines, florfenicol in pigs) (29). Daptomycin 385 is not used in animal production either, but is an option for treating infections with multidrug resistant or vancomycin-resistant enterococci (VRE) in human patients. In line with our very 386 low rate of daptomycin-NWT isolates, most isolates of E. faecium and E. faecalis and all E. 387 388 hirae, E. durans and E. casseliflavus isolates from healthy cattle, pigs and chickens in nine 389 EU countries yielded susceptible isolates (19). Likewise, no daptomycin-resistant E. cecorum 390 strain was present in the collection analysed by Suyemoto et al. in the USA (27). Tigecycline 391 is a glycylcycline developed to overcome tetracycline resistance mechanisms. The activity of 392 this last resort antimicrobial for human medicine appears to have been preserved up to now in enterococci from animals, as the absence of tigecycline resistance in our E. cecorum isolates 393

is in line with the results described for E. faecium, E. hirae, E. durans and E. casseliflavus 394 395 isolates of animal origin (4). The low gentamicin resistance rates are also in line with the 396 findings reported for *E. faecium* and *E. faecalis* from animals in Europe (4) but higher levels 397 were sometimes observed for E. cecorum (6, 17). The prevalence of vancomycin resistance was low, as observed in recent studies of E. cecorum (4). Noteworthy, the vanA operon has 398 already been detected in an *E. cecorum* isolate in Japan (30). Strikingly, although rifampicin 399 400 is not used in poultry production in France, seven isolates were classified as NWT. Resistance 401 to rifampicin in enterococci is usually associated with mutations in the RNA polymerase gene 402 (rpoB), but no mutations specific to E. cecorum NWT isolates were detected.

403 Conclusion. For the first time, the tentative cut-offs for 25 and 20 antimicrobials were 404 determined using respectively DD and BMD methods on a large collection of E. cecorum with clinical and non-clinical origins. Further experiments could confirm or refine these cut-405 406 off values. The DD method seems more appropriate to determine resistance thresholds for this bacterium, as it is more in line with the genetic content. Resistance to medically important 407 408 antimicrobials (imipenem, vancomycin, gentamicin, tigecycline or linezolid) is rare. Mutated GyrA (S83Y or S83V) and ParC (S82I) may explain resistance to some fluoroquinolones. 409 410 Moreover, this study revealed that while some resistances (tetracycline, erythromycin, etc.) are still prevalent, strains of clinical origin showed significant levels of sensitivity for 411 412 antimicrobials authorised for poultry.

413

414 ACKNOWLEDGEMENTS

The authors are grateful to Vincent Cattoir (CHU Rennes, France) for advice in antimicrobial selection, to Avipole (Ploufragan, France), J. Le Guennec (Labofarm, Loudéac, France) and Labocea35 (Fougères, France) who provided caecal contents to isolate commensal isolates, and to Bioscand AB (Täby, Sweden) for providing the NRI tool.

17

bioRxiv preprint doi: https://doi.org/10.1101/2022.10.19.512977; this version posted October 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

419

420 FUNDING

- 421 The authors would like to thank the French National Research Institute for Agriculture, Food
- 422 and Environment (INRAE) and the French Agency for Food, Environmental and
- 423 Occupational Health & Safety (ANSES) for JL's PhD Fellowship. They are also grateful to
- 424 the French Ministry of Agriculture (DGAL) for funding through the Ecoantibio2 programme,
- 425 No. 2018-180. PS acknowledges financial support from INRAE's GISA metaprogramme,
- 426 project CecoType.

427

428

429 **REFERENCES**

- 430 1. Devriese LA, Hommez J, Wijfels R, Haesebrouck F. 1991. Composition of the
- 431 enterococcal and streptococcal intestinal flora of poultry. J Appl Bacteriol 71:46-50.
- 432 <u>https://doi.org/10.1111/j.1365-2672.1991.tb04661.x</u>.
- 433 2. Dolka B, Chrobak-Chmiel D, Czopowicz M, Szeleszczuk P. 2017. Characterization of
- 434 pathogenic *Enterococcus cecorum* from different poultry groups: Broiler chickens,
- 435 layers, turkeys, and waterfowl. PLoS ONE 12
- 436 <u>https://doi.org/10.1371/journal.pone.0185199</u>.
- 437 3. Borst LB, Suyemoto MM, Sarsour AH, Harris MC, Martin MP, Strickland JD, Oviedo
- 438 EO, Barnes HJ. 2017. Pathogenesis of Enterococcal Spondylitis Caused by
- 439 *Enterococcus cecorum* in Broiler Chickens. Vet Pathol 54:61-73.
- 440 https://doi.org/10.1177/0300985816658098.
- 441 4. Jung A, Chen LR, Suyemoto MM, Barnes HJ, Borst LB. 2018. A review of
- 442 *Enterococcus cecorum* infection in poultry. Avian Dis 62:261-271.
- 443 <u>https://doi.org/10.1637/11825-030618-Review.1</u>.
- 444 5. Jung A, Rautenschlein S. 2014. Comprehensive report of an *Enterococcus cecorum*
- infection in a broiler flock in Northern Germany. BMC Vet Res 10
- 446 <u>https://doi.org/10.1186/s12917-014-0311-7</u>.
- 6. Borst LB, Suyemoto MM, Robbins KM, Lyman RL, Martin MP, Barnes HJ. 2012.
- 448 Molecular epidemiology of *Enterococcus cecorum* isolates recovered from
- 449 enterococcal spondylitis outbreaks in the southeastern United States. Avian Pathol
- 450 41:479-485. <u>https://doi.org/10.1080/03079457.2012.718070</u>.
- 451 7. Dolka B, Chrobak-Chmiel D, Makrai L, Szeleszczuk P. 2016. Phenotypic and
- 452 genotypic characterization of *Enterococcus cecorum* strains associated with infections
- 453 in poultry. BMC Vet Res 12 <u>https://doi.org/10.1186/s12917-016-0761-1</u>.

- 455 2015. Antimicrobial resistance, virulence determinants and genetic profiles of clinical
- 456 and nonclinical *Enterococcus cecorum* from poultry. Lett Appl Microbiol 60:111-119.
- 457 <u>https://doi.org/10.1111/lam.12374</u>.
- 458 9. Sharma P, Gupta SK, Barrett JB, Hiott LM, Woodley TA, Kariyawasam S, Frye JG,
- 459 Jackson CR. 2020. Comparison of antimicrobial resistance and pan-genome of clinical
- and non-clinical *Enterococcus cecorum* from poultry using whole-genome sequencing.
- 461 Foods 9 <u>https://doi.org/10.3390/foods9060686</u>.
- 462 10. EUCAST. 2020. Antimicrobial susceptibility testing: EUCAST disk diffusion method,
- 463 Version 8.0
- 464 (<u>https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_docume</u>
- 465 <u>nts/2020_manuals/Manual_v_8.0_EUCAST_Disk_Test_2020.pdf</u>).
- 466 11. EUCAST. 2021. EUCAST reading guide for broth microdilution (Version 3.0)
- 467 https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/MIC_testing/Readi
- 468 <u>ng guide BMD v 3.0 2021.pdf</u>.
- 469 12. Corpet F. 1988. Multiple sequence alignment with hierarchical clustering. Nucleic
- 470 Acids Res 16:10881-90. <u>https://doi.org/10.1093/nar/16.22.10881</u>.
- 471 13. EUCAST. 2017. SOP 10.0 MIC distributions and epidemiological cut-off value
- 472 ECOFF setting
- 473 (https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/EUCAST_SOPs/E
- 474 UCAST_SOP_10.0_MIC_distributions_and_epidemiological_cut-
- 475 <u>off_value_ECOFF_setting_20171117.pdf</u>).
- 476 14. Singer RS, Porter LJ, Schrag NFD, Davies PR, Apley MD, Bjork K. 2020. Estimates
- 477 of on-farm antimicrobial usage in broiler chicken production in the United States,
- 478 2013–2017. Zoonoses Public Health 67:22-35. <u>https://doi.org/10.1111/zph.12764</u>.

- 479 15. EFSA-ECDC. 2014. The European Union Summary Report on antimicrobial
- 480 resistance in zoonotic and indicator bacteria from humans, animals and food in 2012.
- 481 EFSA J 12:3590, 336 pp. <u>https://doi.org/doi:10.2903/j.efsa.2014.3590</u>.
- 482 16. de Jong A, Simjee S, Garch FE, Moyaert H, Rose M, Youala M, Dry M, Group ES.
- 483 2018. Antimicrobial susceptibility of enterococci recovered from healthy cattle, pigs
- 484 and chickens in nine EU countries (EASSA Study) to critically important antibiotics.
- 485 Vet Microbiol 216:168-175. <u>https://doi.org/10.1016/j.vetmic.2018.02.010</u>.
- 486 17. Boerlin P, Nicholson V, Brash M, Slavic D, Boyen F, Sanei B, Butaye P. 2012.
- 487 Diversity of *Enterococcus cecorum* from chickens. Vet Microbiol 157:405-411.
- 488 <u>https://doi.org/10.1016/j.vetmic.2012.01.001</u>.
- 489 18. Schreier J, Karasova D, Crhanova M, Rychlik I, Rautenschlein S, Jung A. 2022.
- 490 Influence of lincomycin-spectinomycin treatment on the outcome of *Enterococcus*
- 491 *cecorum* infection and on the cecal microbiota in broilers. Gut Pathogens 14
- 492 https://doi.org/10.1186/s13099-021-00467-9.
- 493 19. de Jong A, Simjee S, Rose M, Moyaert H, El Garch F, Youala M, Group ES. 2019.
- 494 Antimicrobial resistance monitoring in commensal enterococci from healthy cattle,
- 495 pigs and chickens across Europe during 2004-14 (EASSA Study). J Antimicrob

496 Chemother 74:921-930. <u>https://doi.org/10.1093/jac/dky537</u>.

- 497 20. Aarestrup FM, McNicholas PM. 2002. Incidence of high-level evernimicin resistance
- 498 in *Enterococcus faecium* among food animals and humans. Antimicrob Agents
- 499 Chemother 46:3088-90. <u>https://doi.org/10.1128/AAC.46.9.3088-3090.2002</u>.
- 500 21. Chauvin C, Gicquel-Bruneau M, Perrin-Guyomard A, Humbert F, Salvat G, Guillemot
- 501 D, Sanders P. 2005. Use of avilamycin for growth promotion and avilamycin-
- resistance among *Enterococcus faecium* from broilers in a matched case-control study
- 503 in France. Prev Vet Med 70:155-63. <u>https://doi.org/10.1016/j.prevetmed.2005.03.004</u>.

- 504 22. Anses. 2010. French antimicrobial resistance monitoring program for bacteria of
- animal origin (FARM)- Report 2007-2008

506 (https://www.anses.fr/fr/system/files/SANT-Ra-FARM2008.pdf).

- 507 23. EFSA-ECDC. 2015. The EU Summary Report on antimicrobial resistance in zoonotic
- and indicator bacteria from humans, animals and food in 2013. EFSA J 15:4694.
- 509 <u>https://doi.org/10.2903/j.efsa.2015.4036</u>.
- 510 24. Schwaiger K, Schmied EMV, Bauer J. 2010. Comparative analysis on antibiotic
- 511 resistance characteristics of *Listeria* spp. and *Enterococcus* spp. isolated from laying
- 512 hens and eggs in conventional and organic keeping systems in Bavaria, Germany.
- 513 Zoonoses Public Health 57:171-180. <u>https://doi.org/10.1111/j.1863-</u>
- 514 <u>2378.2008.01229.x</u>.
- 515 25. Wang X, Gao Y, Liu X, Sun N, Huang J, Wang L. 2021. First report of the plasmid-

516 mediated *fosB* gene in *Enterococcus faecalis* from pigs. Genes 12

- 517 <u>https://doi.org/10.3390/genes12111684</u>.
- 518 26. Zhang X, Bi W, Chen L, Zhang Y, Fang R, Cao J, Zhou T. 2020. Molecular
- 519 mechanisms and epidemiology of fosfomycin resistance in enterococci isolated from
- 520 patients at a teaching hospital in China, 2013–2016. J Global Antimicrob Resist
- 521 20:191-196. <u>https://doi.org/10.1016/j.jgar.2019.08.006</u>.
- 522 27. Suyemoto MM, Barnes HJ, Borst LB. 2017. Culture methods impact recovery of
- 523 antibiotic-resistant enterococci including *Enterococcus cecorum* from pre- and
- 524 postharvest chicken. Lett Appl Microbiol 64:210-216.
- 525 <u>https://doi.org/10.1111/lam.12705</u>.
- 526 28. Timmermans M, Bogaerts B, Vanneste K, De Keersmaecker SCJ, Roosens NHC,
- 527 Kowalewicz C, Simon G, Argudín MA, Deplano A, Hallin M, Wattiau P, Fretin D,
- 528 Denis O, Boland C. 2021. Large diversity of linezolid-resistant isolates discovered in

- 529 food-producing animals through linezolid selective monitoring in Belgium in 2019. J
- 530 Antimicrob Chemother 77:49-57. <u>https://doi.org/10.1093/jac/dkab376</u>.
- 531 29. Fioriti S, Morroni G, Coccitto SN, Brenciani A, Antonelli A, Di Pilato V, Baccani I,
- 532 Pollini S, Cucco L, Morelli A, Paniccià M, Magistrali CF, Rossolini GM, Giovanetti
- E. 2020. Detection of oxazolidinone resistance genes and characterization of genetic
- environments in enterococci of Swine origin, Italy. Microorg 8:1-19.
- 535 https://doi.org/10.3390/microorganisms8122021.
- 536 30. Harada T, Kawahara R, Kanki M, Taguchi M, Kumeda Y. 2012. Isolation and
- 537 characterization of *vanA* genotype vancomycin-resistant *Enterococcus cecorum* from
- retail poultry in Japan. Int J Food Microbiol 153:372-377.
- 539 <u>https://doi.org/10.1016/j.ijfoodmicro.2011.11.029</u>.
- 540
- 541

542 Figure legends

543 Figure 1: MIC results and CO_{WT} determination. White fields represent the range of 544 dilutions tested. MIC values equal to or lower than the lowest concentration tested are 545 presented as the lowest concentration. MIC values greater than the highest concentration 546 tested are presented as one dilution step above the test range. A black vertical line indicates 547 that the CO_{WT} value was calculated with the ECOFFinder tool. A dotted line indicates that the 548 CO_{WT} value was determined by visual inspection (not enough WT isolates to calculate it). No 549 CO_{WT} could be determined for ampicillin, amoxicillin and spectinomycin. ^a Quinu-Dalfo: Quinupristin-Dalfopristin 550 551 Figure 2: Heatmap of *E. cecorum* antimicrobial sensitivity determined by the disc 552 diffusion method. Determination of WT (white), non-WT (black) and non-determined (grey)

- status for each antimicrobial. NCP: non-clinical poultry isolate, CP: clinical poultry isolate,
- 554 CH: clinical human isolate. ND: CO_{WT} was not determined.
- **Table 1:** Non-wild-type isolates according to their clinical origin.
- **Table 2:** Comparison of *E. cecorum* CO_{WT} values with *S. pneumoniae*, *E. faecalis*, *E. faecium*
- 557 or criteria previously used for *E. cecorum*.
- 558 Supplementary material
- **Table S1:** Isolates used in the study.
- 560 **Table S2:** Scattergram comparing MICs and inhibition zone diameters.
- Table S3: CO_{WT} values, inhibition zone diameters and interpretations for the disc diffusion
 method.
- **Table S4:** Gene content, mutations and phenotype of resistance in 118 *E. cecorum* isolates.
- 564 Figure S1: Distribution of inhibition zone diameters and NRI method for CO_{WT}
- 565 determination. A. Quinupristin-Dalfopristin; B. Erythromycin; C. Vancomycin; D.

bioRxiv preprint doi: https://doi.org/10.1101/2022.10.19.512977; this version posted October 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

- 566 Amoxicillin. The orange dotted line represents the CO_{WT} value determined. No CO_{WT} could
- 567 be determined for amoxicillin.

568

Table 1: Non-wild-type isolates according to their clinical origin.

	CP ^a (n=113)	NCP ^a (n=89)	P-value ^c
Antimicrobial	No. NWT ^b (%)	No. NWT ^b (%)	
Norfloxacin	36 (32%)	16 (18%)	0.025
Ciprofloxacin	2 (2%)	3 (3%)	0.66
Levofloxacin	3 (3%)	3 (3%)	1
Vancomycin	7 (6%)	1 (1%)	0.08
Teicoplanin	1 (1%)	0 (0%)	1
Gentamicin	0 (0%)	1 (1%)	0.44
Streptomycin	2 (2%)	3 (3%)	0.66
Spectinomycin	4 (4%)	19 (21%)	8.19x10 ⁻⁵
Lincomycin/Spectinomycin	9 (8%)	19 (21%)	6x10 ⁻³
Lincomycin	75 (66%)	47 (53%)	0.05
Erythromycin	74 (65%)	36 (40%)	3.8x10 ⁻⁴
Spiramycin	67 (59%)	29 (33%)	1.6x10 ⁻⁴
Tylosin	66 (58%)	29 (33%)	2.6x10⁻⁴
Quinupristin/dalfopristin	7 (6%)	5 (6%)	0.86
Tetracycline	111 (98%)	83 (93%)	0.14
Doxycycline	108 (96%)	82 (92%)	0.3
Tigecycline	0 (0%)	0 (0%)	1
Tiamulin	9 (8%)	18 (20%)	0.01
Fosfomycin	1 (1%)	1 (1%)	1
Nitrofurantoin	1 (1%)	1 (1%)	1
Linezolid	2 (2%)	0 (0%)	1
Chloramphenicol	0 (0%)	1 (1%)	1
Bacitracin	26 (23%)	29 (33%)	0.12
Rifampicin	6 (5%)	1 (1%)	0.14

^a CP for clinical poultry and NCP for non-clinical poultry isolates

^b WT for wild-type isolates and NWT for non-wild-type isolates according to the disc diffusion method ^c P-value calculated with Chi² or Fisher exact test if n≤5. Significant p-values are in bold.

	Broth micro-dilution MIC (mg/L)				Disc diffusion Inhibition zone diameter (mm)				
Antimicrobial	CO _{wt} E. cecorun	S. pnª	ECOFF <i>E.</i> faecalis	ECOFF <i>E.</i> faecium	Other criteria ^b	CO _{wt} E. cecorum	ECOFF <i>S.pn</i>	ECOFF <i>E.</i> faecium	ECOFF <i>E.</i> faecalis
Ampicillin	ND	0.06	4	8	0.25 ^d (AMX)	ND	(28)	10	10
Avilamycin	1		8	16					
Bacitracin	4		(32) ^f	32		22			
Chloramphenicol	8	8	32	32	16 ^e	22	21		
Ciprofloxacin	4	4	4	8	0.5 ^e (ENR ^g) 2 ^e	12	(18)		
Daptomycin	0.25	(0.5) ^f	4	8	4 ^e				
Doxycycline	1	0.5	0.5	0.5		24			
Erythromycin	0.5	0.25	4	4	0.5 ^d 4 ^e	21	22		
Fosfomycin			128			18			
Gentamicin	4		64	32	4 ^c 250 ^d	15		8	8
Imipenem		0.016	4	4		21		21	21
Levofloxacin	2	2	4	4		13	19		
Linezolid	8	4	ID	4	4 ^e	21	(22)	19	19
Nitrofurantoin			(32) [†]	256		21			15
Norfloxacin						18	12		12
Quinupristin- dalfopristin	4				2 ^e	20			
Rifampicin	1	(0.125) [†]				22	25		
Streptomycin	32		512	128	512 [°] 500°	15		-	-
Teicoplanin	1	0.25	2	2		14	(18) ^f	(16) ^f	(16) ^f
Tetracycline	2	1	4	4	4 ^c 8 ^e	27	25		
Tigecycline	4	0.125	0.25	0.25	0.25 ^e	19			18
Tylosin	8				2 ^d 16 ^e	15			
Vancomycin	2	1	4	4	16 ^e	15	(16) ^f	12	12


Table 2 – Comparison of E. cecorum CO_{WT} values with S. pneumoniae, E. faecalis, E. faecium ECOFF or criteria previously used for *E. cecorum*.

^a S. pn : Streptococcus pneumoniae

^b Criteria used by Borst et al. (Borst et al., 2012) based on ^c breakpoints for enterococci (Clinical Laboratory Standards Institute, 2010) or ^d stratification using the overall median concentration into susceptible (below the median) and non-susceptible (above the median) or ^e criteria used by Jackson et al. (Jackson et al., 2015). ^f EUCAST tentative ECOFF


^g ENR for enrofloxacin

ECOFF values are obtained from the EUCAST website (mic.eucast.org/search/)



isolate, CH: clinical human isolate. ND: ${\sf CO}_{{\sf WT}}$ was not determined

bioRxiv preprint doi: https://doi.org/10.1101/2022.10.19.512977; this version posted October 21, 2022. The copyright holder for this preprint (which was not certified by beer review) is the author for the author for the preprint of the author for the author for



isolate, CH: clinical human isolate. ND: $\mathrm{CO}_{\mathrm{WT}}$ was not determined

bioRxiv preprint doi: https://doi.org/10.1101/2022.10.19.512977; this version posted October 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/fonder and the presence of the preview.